Open AccessAngiotensin converting enzyme inhibitors versus angiotensin II type 1 receptor blockers in patients with acute myocardial infarction and prediabetes after successful implantation of newer-generation drug-eluting stents
Author(s) -
Yong Hoon Kim,
Ae-Young Her,
Myung Ho Jeong,
ByeongKeuk Kim,
SungJin Hong,
Sang-Ho Park,
Seunghwan Kim,
ChulMin Ahn,
Jung-Sun Kim,
YoungGuk Ko,
Donghoon Choi,
Myeong–Ki Hong,
Yangsoo Jang
Publication year - 2023
Publication title -
cardiology journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.573
H-Index - 33
eISSN - 1897-5593
pISSN - 1898-018X
DOI - 10.5603/cj.a2021.0116
Subject(s) - medicine , hazard ratio , myocardial infarction , cardiology , prediabetes , clinical endpoint , revascularization , confidence interval , diabetes mellitus , type 2 diabetes , clinical trial , endocrinology
Because limited data are available, the present study investigated 2-year major clinical outcomes after angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs) therapy in patients with acute myocardial infarction (AMI) and prediabetes after successful implantation of newer-generation drug-eluting stents (DESs).